ACG Wealth’s Helus Pharma Inc. Common Stock HELP Stock Holding History

ACG Wealth’s Portfolio HELP Stock Details HELP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	394
2022 Q2	$0	Buy	+1	New	+$24	﹤0.01%	941

Other funds holding HELP

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

IAG Wealth Partners Waukesha, Wisconsin $1.01B AUM 17.58% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.95B AUM 25.45% 1-Year Est. Return

ACG Wealth's HELP Position: Q3 2022 in Review

ACG Wealth sold out of Helus Pharma Inc. Common Stock (HELP) in Q3 2022, closing a stake of 1 share.

ACG Wealth first reported a position in HELP in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 61 funds tracked by Wall St. Rank hold HELP as of Q3 2022.

ACG Wealth reported no remaining Helus Pharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 1 Helus Pharma Inc. Common Stock share in Q3 2022.
ACG Wealth first reported a position in Helus Pharma Inc. Common Stock in Q2 2022 and held it in 1 quarter.
ACG Wealth's Helus Pharma Inc. Common Stock position peaked at $0 in Q2 2022.
61 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.